Previous 10 | Next 10 |
2023-05-15 07:38:20 ET Minerva Neurosciences press release ( NASDAQ: NERV ): Q1 GAAP EPS of -$1.31. Cash, cash equivalents, and restricted cash as of March 31, 2023 were approximately $36.1 million, compared to $36.2 million as of December 31, 2022. For further detai...
BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first qua...
2023-05-10 09:06:14 ET The U.S. Food and Drug Administration (FDA) accepted to review Minerva Neurosciences' ( NASDAQ: NERV ) application seeking approval of roluperidone to treat negative symptoms in patients with schizophrenia. Earlier in May, the FDA filed the com...
BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release first quarter 2023 financial...
2023-05-01 13:03:11 ET Gainers: Sentage Holdings ( SNTG ) +268% . Quhuo Limited ( QH ) +160% . Midwest Holding ( MDWT ) +87% . Baosheng Media Group Holdings Limited ( BAOS ) +76% . Meihua International Medical Technologies ( MHUA ) ...
Minerva Neurosciences, Inc. (NASDAQ: NERV) is one of today's top gainers. The company's shares are currently up 58.66% on the day to $4.39. Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the tr...
2023-05-01 10:03:58 ET Gainers: Nano-X Imaging ( NNOX ) +53% . Meihua International Medical Technologies ( MHUA ) +34% . Minerva Neurosciences ( NERV ) +27% . Apollomics ( APLM ) +24% . Ascendis Pharma ( ASND ) +19% . ...
2023-05-01 08:28:28 ET Minerva Neurosciences ( NASDAQ: NERV ) said the U.S. Food and Drug Administration (FDA) filed the company's new drug application (NDA) for roluperidone to treat negative symptoms in patients with schizophrenia. The decision to file the NDA follows Minerv...
BURLINGTON, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) ...
2023-04-26 10:09:11 ET Gainers: Scilex Holding ( SCLX ) +14% . Cytek Biosciences ( CTKB ) +12% . Minerva Neurosciences ( NERV ) +10% . Vincerx Pharma ( VINC ) +9% . LianBio ( LIAN ) +7% . Losers: ZyVersa Therapeutics ( Z...
News, Short Squeeze, Breakout and More Instantly...
Minerva Neurosciences Inc Company Name:
NERV Stock Symbol:
NASDAQ Market:
Minerva Neurosciences Inc Website:
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first q...
A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 19.3% to $6.86 on volume of 301,330,136 shares Canoo Inc. (GOEV) rose 8.3% to $0.1138 on volume of 118,801,751 shares Ault Alliance Inc. (AULT) rose 19.1% to $0.4642 on volume of 117,184,555 shares Mar...